Tony Berberabe, MPH


Enfortumab Vedotin highly active in cisplatin-ineligible urothelial cancer

February 25, 2021

Based on these findings, an application has been filed with the FDA to expand enfortumab vedotin’s approval to include cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor.